Stefania Cannito

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2338739/publications.pdf

Version: 2024-02-01

43 papers

2,714 citations

236925 25 h-index 265206 42 g-index

43 all docs

43 docs citations

times ranked

43

4173 citing authors

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 459-482. | 4.5 | 13 |
| 2 | Oncostatin <scp>M</scp> is overexpressed in <scp>NASH</scp> â€related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis. Journal of Pathology, 2022, 257, 82-95. | 4.5 | 12 |
| 3 | Hyaluronated and PEGylated Liposomes as a Potential Drug-Delivery Strategy to Specifically Target Liver Cancer and Inflammatory Cells. Molecules, 2022, 27, 1062. | 3.8 | 14 |
| 4 | G protein–coupled receptor 21 in macrophages: An in vitro study. European Journal of Pharmacology, 2022, 926, 175018. | 3.5 | 3 |
| 5 | Hepatic Myofibroblasts: A Heterogeneous and Redox-Modulated Cell Population in Liver Fibrogenesis. Antioxidants, 2022, 11, 1278. | 5.1 | 8 |
| 6 | Hypoxia, Hypoxia-Inducible Factors and Liver Fibrosis. Cells, 2021, 10, 1764. | 4.1 | 35 |
| 7 | GPR21 Inhibition Increases Glucose-Uptake in HepG2 Cells. International Journal of Molecular Sciences, 2021, 22, 10784. | 4.1 | 3 |
| 8 | Oncostatin M, A Profibrogenic Mediator Overexpressed in Non-Alcoholic Fatty Liver Disease, Stimulates Migration of Hepatic Myofibroblasts. Cells, 2020, 9, 28. | 4.1 | 26 |
| 9 | Liver fibrogenesis: un update on established and emerging basic concepts. Archives of Biochemistry and Biophysics, 2020, 689, 108445. | 3.0 | 15 |
| 10 | ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis. International Journal of Molecular Sciences, 2019, 20, 2700. | 4.1 | 72 |
| 11 | SerpinB3 Differently Up-Regulates Hypoxia Inducible Factors -1α and -2α in Hepatocellular Carcinoma: Mechanisms Revealing Novel Potential Therapeutic Targets. Cancers, 2019, 11, 1933. | 3.7 | 22 |
| 12 | Hyaluronated mesoporous silica nanoparticles for active targeting: influence of conjugation method and hyaluronic acid molecular weight on the nanovector properties. Journal of Colloid and Interface Science, 2018, 516, 484-497. | 9.4 | 33 |
| 13 | Hypoxiaâ€inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidineâ€rich glycoprotein. Hepatology, 2018, 67, 2196-2214. | 7.3 | 66 |
| 14 | Effects of the rare elements lanthanum and cerium on the growth of colorectal and hepatic cancer cell lines. Toxicology in Vitro, 2018, 46, 9-18. | 2.4 | 34 |
| 15 | Serpinb3 is Overexpressed in the Liver in Presence of Iron Overload. Journal of Investigative Medicine, 2018, 66, 32-38. | 1.6 | 2 |
| 16 | Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies. International Journal of Molecular Sciences, 2018, 19, 3875. | 4.1 | 21 |
| 17 | Therapeutic pro-fibrogenic signaling pathways in fibroblasts. Advanced Drug Delivery Reviews, 2017, 121, 57-84. | 13.7 | 51 |
| 18 | SerpinB3 Promotes Pro-fibrogenic Responses in Activated Hepatic Stellate Cells. Scientific Reports, 2017, 7, 3420. | 3.3 | 23 |

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. PLoS ONE, 2017, 12, e0172575. | 2.5 | 49 |
| 20 | In vivo reprogramming of hepatic myofibroblasts into hepatocytes attenuates liver fibrosis: back to the future?. Stem Cell Investigation, 2016, 3, 53-53. | 3.0 | 1 |
| 21 | SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity. Scientific Reports, 2016, 5, 17701. | 3.3 | 31 |
| 22 | Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells. Oncotarget, 2015, 6, 2206-2221. | 1.8 | 59 |
| 23 | The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. Gut, 2015, 64, 1454-1465. | 12.1 | 58 |
| 24 | Hepatic myofibroblasts and fibrogenic progression of chronic liver diseases. Histology and Histopathology, 2015, 30, 1011-32. | 0.7 | 18 |
| 25 | Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness. Expert Opinion on Therapeutic Targets, 2014, 18, 121-135. | 3.4 | 102 |
| 26 | Cellular and molecular mechanisms in liver fibrogenesis. Archives of Biochemistry and Biophysics, 2014, 548, 20-37. | 3.0 | 177 |
| 27 | Hypoxia, hypoxia-inducible factors and fibrogenesis in chronic liver diseases. Histology and Histopathology, 2014, 29, 33-44. | 0.7 | 37 |
| 28 | Hepatic Angiogenesis and Fibrogenesis in the Progression of Chronic Liver Diseases. Current Angiogenesis, 2013, 2, 23-29. | 0.1 | 3 |
| 29 | The biphasic nature of hypoxiaâ€induced directional migration of activated human hepatic stellate cells. Journal of Pathology, 2012, 226, 588-597. | 4.5 | 71 |
| 30 | Celecoxib inactivates epithelial–mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells. Molecular Carcinogenesis, 2012, 51, 783-795. | 2.7 | 30 |
| 31 | Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells. Journal of Hepatology, 2011, 54, 964-974. | 3.7 | 109 |
| 32 | Dissection of the Biphasic Nature of Hypoxia-Induced Motogenic Action in Bone Marrow-Derived Human Mesenchymal Stem Cells. Stem Cells, 2011, 29, 952-963. | 3.2 | 51 |
| 33 | SERPINB3 induces epithelial–mesenchymal transition. Journal of Pathology, 2010, 221, 343-356. | 4.5 | 77 |
| 34 | Epithelial–Mesenchymal Transition: From Molecular Mechanisms, Redox Regulation to Implications in Human Health and Disease. Antioxidants and Redox Signaling, 2010, 12, 1383-1430. | 5.4 | 226 |
| 35 | Liver fibrosis: a dynamic and potentially reversible process. Histology and Histopathology, 2010, 25, 1075-91. | 0.7 | 110 |
| 36 | Hepatic myofibroblasts: A heterogeneous population of multifunctional cells in liver fibrogenesis. International Journal of Biochemistry and Cell Biology, 2009, 41, 2089-2093. | 2.8 | 87 |

| # | Article | IF | CITATION |
|----|--|------|----------|
| 37 | Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut, 2008, 57, 223-231. | 12.1 | 248 |
| 38 | ß-Catenin triggers nuclear factor ?B-dependent up-regulation of hepatocyte inducible nitric oxide synthase. International Journal of Biochemistry and Cell Biology, 2008, 40, 1861-1871. | 2.8 | 17 |
| 39 | Redox mechanisms switch on hypoxia-dependent epithelial–mesenchymal transition in cancer cells. Carcinogenesis, 2008, 29, 2267-2278. | 2.8 | 274 |
| 40 | Proangiogenic Cytokines as Hypoxia-Dependent Factors Stimulating Migration of Human Hepatic Stellate Cells. American Journal of Pathology, 2007, 170, 1942-1953. | 3.8 | 196 |
| 41 | Dose dependent and divergent effects of superoxide anion on cell death, proliferation, and migration of activated human hepatic stellate cells. Gut, 2006, 55, 90-97. | 12.1 | 78 |
| 42 | Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut, 2005, 55, 1174-1182. | 12.1 | 143 |
| 43 | SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease. Frontiers in Immunology, 0, 13 , . | 4.8 | 9 |